S
Su-Peng Yeh
Researcher at China Medical University (Taiwan)
Publications - 99
Citations - 3490
Su-Peng Yeh is an academic researcher from China Medical University (Taiwan). The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 19, co-authored 74 publications receiving 1999 citations. Previous affiliations of Su-Peng Yeh include China Medical University (PRC).
Papers
More filters
Journal ArticleDOI
Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia
Courtney D. DiNardo,Brian A. Jonas,Vinod Pullarkat,Michael J. Thirman,Jacqueline S. Garcia,Andrew H. Wei,Marina Konopleva,Hartmut Döhner,Anthony Letai,Pierre Fenaux,Elizabeth A. Koller,Violaine Havelange,Brian Leber,Jordi Esteve,Jianxiang Wang,Vlatko Pejša,Roman Hájek,Kimmo Porkka,Árpád Illés,David Lavie,Roberto M. Lemoli,Kazuhito Yamamoto,Sung-Soo Yoon,Jun-Ho Jang,Su-Peng Yeh,Mehmet Turgut,Wan-Jen Hong,Ying Zhou,Jalaja Potluri,Keith W. Pratz +29 more
TL;DR: In previously untreated patients with confirmed AML who were ineligible for intensive chemotherapy, overall survival was longer and the incidence of remission was higher among patients who received azacitidine plus venetoclax than among those who received zsitidine alone.
Journal ArticleDOI
Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial
Steven M. Horwitz,Owen A. O'Connor,Barbara Pro,Timothy M Illidge,Michelle A. Fanale,Ranjana H. Advani,Nancy L. Bartlett,Jacob Haaber Christensen,Franck Morschhauser,Eva Domingo-Domenech,Giuseppe Rossi,Won Seog Kim,Tatyana Feldman,Anne Lennard,David Belada,Árpád Illés,Kensei Tobinai,Kunihiro Tsukasaki,Su-Peng Yeh,Andrei R. Shustov,Andreas Hüttmann,Kerry J. Savage,Sam Yuen,Swaminathan Padmanabhan Iyer,Pier Luigi Zinzani,Zhaowei Hua,Meredith Little,Shangbang Rao,Joseph Woolery,Thomas Manley,Lorenz Trümper +30 more
TL;DR: Front-line treatment with A+CHP is superior to CHOP for patients with CD30-positive peripheral T-cell lymphomas as shown by a significant improvement in progression-free survival and overall survival with a manageable safety profile.
Journal ArticleDOI
CDK1-dependent phosphorylation of EZH2 suppresses methylation of H3K27 and promotes osteogenic differentiation of human mesenchymal stem cells.
Yongkun Wei,Ya Huey Chen,Long Yuan Li,Long Yuan Li,Jingyu Lang,Su-Peng Yeh,Bin Shi,Cheng Chieh Yang,Jer Yen Yang,Chun Yi Lin,Chien-Chen Lai,Chien-Chen Lai,Mien Chie Hung +12 more
TL;DR: It is demonstrated that EZH2 can be phosphorylated at Thr 487 through activation of cyclin-dependent kinase 1 (CDK1) and defined a signalling link between CDK1 and EZh2 that may have an important role in diverse biological processes, including cancer-cell invasion and osteogenic differentiation of mesenchymal stem cells.
Journal ArticleDOI
Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non-Germinal Center B-Cell Diffuse Large B-Cell Lymphoma
Anas Younes,Laurie H. Sehn,Peter Johnson,Pier Luigi Zinzani,Xiaonan Hong,Jun Zhu,Caterina Patti,David Belada,Olga Samoilova,Cheolwon Suh,Sirpa Leppä,Shinya Rai,Mehmet Turgut,Wojciech Jurczak,Matthew C. Cheung,Ronit Gurion,Ronit Gurion,Su-Peng Yeh,Andres Lopez-Hernandez,Ulrich Dührsen,Catherine Thieblemont,C.S. Chiattone,Sriram Balasubramanian,Jodi Carey,Grace Liu,S. Martin Shreeve,Steven Sun,Sen Hong Zhuang,Jessica Vermeulen,Louis M. Staudt,Wyndham H. Wilson +30 more
TL;DR: The study did not meet its primary end point in the intent-to-treat (ITT) population and the activated B-cell (ABC) DLBCL subgroup, but in patients age younger than 60 years, ibrutinib plus R-CHOP improved EFS, PFS, and OS with manageable safety.
Journal ArticleDOI
Randomized, Double-Blind, Phase III Trial of Enzastaurin Versus Placebo in Patients Achieving Remission After First-Line Therapy for High-Risk Diffuse Large B-Cell Lymphoma
Michael Crump,Sirpa Leppä,Luis Fayad,Je-Jung Lee,Alice Di Rocco,Michinori Ogura,Hans Hagberg,Frederick J. Schnell,Robert M. Rifkin,Andreas Mackensen,Fritz Offner,Lauren Pinter-Brown,Sonali M. Smith,Kensei Tobinai,Su-Peng Yeh,Eric D. Hsi,Tuan Nguyen,Peipei Shi,Marjo Hahka-Kemppinen,Don Thornton,Boris Lin,Brad S. Kahl,Norbert Schmitz,Kerry J. Savage,Thomas M. Habermann +24 more
TL;DR: Enzastaurin did not significantly improve DFS in patients with high-risk DLBCL after achieving complete response to R-CHOP, and achievement of a complete response may have abrogated the prognostic significance of cell of origin by immunohistochemistry.